AR097556A1 - Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas - Google Patents
Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativasInfo
- Publication number
- AR097556A1 AR097556A1 ARP140103309A ARP140103309A AR097556A1 AR 097556 A1 AR097556 A1 AR 097556A1 AR P140103309 A ARP140103309 A AR P140103309A AR P140103309 A ARP140103309 A AR P140103309A AR 097556 A1 AR097556 A1 AR 097556A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- treatment
- combination
- erk
- hyperproliferative diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un método para el tratamiento de un trastorno hiperproliferativo que comprende administrar a un mamífero que lo necesita una cantidad terapéutica eficaz de una combinación de un inhibidor de MEK, o una sal farmacéuticamente aceptable, y un inhibidor de ERK, o una sal farmacéuticamente aceptable, tanto como una formulación combinada o como mediante una forma alternada. Reivindicación 2: El método de la reivindicación 1 en el que el trastorno hiperproliferativo es cáncer y el mamífero es un ser humano. Reivindicación 4: El método de cualquiera de las reivindicaciones 2 ó 3 en el que el inhibidor de MEK es cobimetinib. Reivindicación 10: El método de una cualquiera de las reivindicaciones 2 - 9 en el que el inhibidor de ERK es (S)-1-(1-(4-cloro-3-fluorofeni1)-2-hidroxieti1)-4-(2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)piridin-2(1H)-ona o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874206P | 2013-09-05 | 2013-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097556A1 true AR097556A1 (es) | 2016-03-23 |
Family
ID=51492945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140103309A AR097556A1 (es) | 2013-09-05 | 2014-09-04 | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9532987B2 (es) |
| EP (1) | EP3041471A1 (es) |
| JP (2) | JP2016531139A (es) |
| KR (1) | KR20160048807A (es) |
| CN (1) | CN105517548B (es) |
| AR (1) | AR097556A1 (es) |
| AU (1) | AU2014317119B2 (es) |
| CA (1) | CA2916619A1 (es) |
| CL (1) | CL2016000042A1 (es) |
| EA (1) | EA034872B1 (es) |
| HK (1) | HK1218072A1 (es) |
| IL (1) | IL243251B (es) |
| MA (1) | MA38827A1 (es) |
| MX (1) | MX370417B (es) |
| PE (1) | PE20160529A1 (es) |
| PH (1) | PH12016500270A1 (es) |
| SG (1) | SG11201600989VA (es) |
| TW (1) | TW201605477A (es) |
| UA (1) | UA120423C2 (es) |
| WO (1) | WO2015032840A1 (es) |
| ZA (1) | ZA201600091B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3321262T1 (sl) * | 2012-03-01 | 2021-04-30 | Array Biopharma, Inc. | Inhibitorji serin/treonin kinaze |
| KR102359759B1 (ko) | 2013-12-06 | 2022-02-09 | 제넨테크, 인크. | 세린/트레오닌 키나제 저해제 |
| CA2934709C (en) * | 2013-12-30 | 2022-08-30 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| JP6877423B2 (ja) | 2015-11-09 | 2021-05-26 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | がんの処置において有用なジヒドロイミダゾピラジノン誘導体 |
| WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| CN105330643B (zh) | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| AU2017249229A1 (en) * | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| EP3503922B1 (en) * | 2016-08-23 | 2022-10-26 | Genentech, Inc. | Combination therapy for the treatment of pancreatic cancer |
| DK3425390T3 (da) * | 2016-11-25 | 2021-02-15 | Genuv Inc | Sammensætning til fremme af differentiering og beskyttelse af neurale stamceller og fremgangsmåde til induktion af neural regenerering ved anvendelse heraf |
| JP2019019094A (ja) * | 2017-07-19 | 2019-02-07 | 学校法人福岡大学 | 変異ｋｒａｓ関連シグナル阻害用組成物 |
| AU2018329925A1 (en) | 2017-09-08 | 2020-03-05 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for cancer |
| US11395823B2 (en) | 2018-01-09 | 2022-07-26 | Duke University | Topical administration of MEK inhibiting agents for the treatment of skin disorders |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| US20220265584A1 (en) * | 2019-07-11 | 2022-08-25 | Emory University | Combination Therapies for Managing Cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025871B9 (ru) | 2005-10-07 | 2017-08-31 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
| ATE531720T1 (de) | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| CL2007003444A1 (es) | 2006-11-30 | 2008-06-27 | Genentech Inc | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| EP2164850B1 (en) | 2007-06-12 | 2016-01-13 | Genentech, Inc. | N-substituted azaindoles and methods of use |
| RU2498985C2 (ru) | 2007-12-19 | 2013-11-20 | Дженентек, Инк. | 8-анилиноимидазопиридины и способы их использования |
| PE20131210A1 (es) | 2007-12-19 | 2013-10-31 | Genentech Inc | Derivados de 5-anilinoimidazopiridina como inhibidores de mek |
| CA2708176A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
| US8492427B2 (en) | 2008-07-01 | 2013-07-23 | Genentech, Inc. | Isoindolones derivatives as MEK kinase inhibitors and methods of use |
| PE20110570A1 (es) | 2008-07-01 | 2011-08-26 | Genentech Inc | Heterociclos biciclicos sustituidos |
| WO2011028540A1 (en) | 2009-08-24 | 2011-03-10 | Genentech, Inc. | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
| EP2488178B1 (en) | 2009-10-12 | 2016-11-16 | F.Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
| KR101923364B1 (ko) | 2010-11-23 | 2018-11-30 | 애브비 인코포레이티드 | 아폽토시스유도제의 염 및 결정형 |
| ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| BR112014002675A2 (pt) | 2011-08-04 | 2017-02-21 | Array Biopharma Inc | "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição" |
| SI3321262T1 (sl) | 2012-03-01 | 2021-04-30 | Array Biopharma, Inc. | Inhibitorji serin/treonin kinaze |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| WO2013178569A1 (en) | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Pyrrolidino heterocycles |
| BR112015003418A2 (pt) | 2012-08-17 | 2017-07-04 | Hoffmann La Roche | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
| AR092253A1 (es) | 2012-08-27 | 2015-04-08 | Array Biopharma Inc | Inhibidores de serina/treonina cinasa |
| CR20200237A (es) | 2012-10-12 | 2020-07-26 | Exelixis Inc | Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer (diviisional 2015-0245) |
| KR20150068956A (ko) | 2012-10-16 | 2015-06-22 | 에프. 호프만-라 로슈 아게 | 세린/트레오닌 키나아제 억제제 |
| KR102359759B1 (ko) | 2013-12-06 | 2022-02-09 | 제넨테크, 인크. | 세린/트레오닌 키나제 저해제 |
| BR112016015235A2 (pt) | 2013-12-30 | 2017-08-08 | Genentech Inc | Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento |
| CA2934709C (en) | 2013-12-30 | 2022-08-30 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
| TWI762806B (zh) | 2014-04-09 | 2022-05-01 | 美商建南德克公司 | 作為ｅｒｋ抑制劑之化合物 |
-
2014
- 2014-08-29 US US14/473,311 patent/US9532987B2/en not_active Expired - Fee Related
- 2014-09-04 EA EA201690513A patent/EA034872B1/ru not_active IP Right Cessation
- 2014-09-04 KR KR1020167005716A patent/KR20160048807A/ko not_active Application Discontinuation
- 2014-09-04 AR ARP140103309A patent/AR097556A1/es unknown
- 2014-09-04 PE PE2016000076A patent/PE20160529A1/es unknown
- 2014-09-04 UA UAA201603616A patent/UA120423C2/uk unknown
- 2014-09-04 EP EP14761328.5A patent/EP3041471A1/en not_active Withdrawn
- 2014-09-04 MX MX2016002857A patent/MX370417B/es active IP Right Grant
- 2014-09-04 CN CN201480048950.XA patent/CN105517548B/zh not_active Expired - Fee Related
- 2014-09-04 MA MA38827A patent/MA38827A1/fr unknown
- 2014-09-04 JP JP2016539537A patent/JP2016531139A/ja not_active Withdrawn
- 2014-09-04 TW TW103130648A patent/TW201605477A/zh unknown
- 2014-09-04 WO PCT/EP2014/068776 patent/WO2015032840A1/en active Application Filing
- 2014-09-04 SG SG11201600989VA patent/SG11201600989VA/en unknown
- 2014-09-04 AU AU2014317119A patent/AU2014317119B2/en not_active Expired - Fee Related
- 2014-09-04 CA CA2916619A patent/CA2916619A1/en not_active Abandoned
-
2015
- 2015-12-21 IL IL243251A patent/IL243251B/en not_active IP Right Cessation
-
2016
- 2016-01-06 ZA ZA2016/00091A patent/ZA201600091B/en unknown
- 2016-01-08 CL CL2016000042A patent/CL2016000042A1/es unknown
- 2016-02-09 PH PH12016500270A patent/PH12016500270A1/en unknown
- 2016-05-30 HK HK16106100.6A patent/HK1218072A1/zh unknown
-
2018
- 2018-10-03 JP JP2018188348A patent/JP2019031517A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019031517A (ja) | 2019-02-28 |
| TW201605477A (zh) | 2016-02-16 |
| MX2016002857A (es) | 2016-06-22 |
| US9532987B2 (en) | 2017-01-03 |
| PH12016500270A1 (en) | 2016-05-16 |
| CN105517548A (zh) | 2016-04-20 |
| EA201690513A1 (ru) | 2016-07-29 |
| AU2014317119A1 (en) | 2016-03-03 |
| EA034872B1 (ru) | 2020-03-31 |
| PE20160529A1 (es) | 2016-05-21 |
| SG11201600989VA (en) | 2016-03-30 |
| JP2016531139A (ja) | 2016-10-06 |
| WO2015032840A1 (en) | 2015-03-12 |
| CL2016000042A1 (es) | 2016-08-05 |
| HK1218072A1 (zh) | 2017-02-03 |
| AU2014317119B2 (en) | 2019-12-05 |
| EP3041471A1 (en) | 2016-07-13 |
| KR20160048807A (ko) | 2016-05-04 |
| US20150111869A1 (en) | 2015-04-23 |
| IL243251B (en) | 2019-02-28 |
| CA2916619A1 (en) | 2015-03-12 |
| MX370417B (es) | 2019-12-10 |
| ZA201600091B (en) | 2017-04-26 |
| UA120423C2 (uk) | 2019-12-10 |
| CN105517548B (zh) | 2020-01-21 |
| MA38827A1 (fr) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097556A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| CR20160069A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| IN2015DN00376A (es) | ||
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| CR20140388A (es) | Compuestos terapeuticamente activos y sus métodos de uso | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
| SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PE20160223A1 (es) | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 | |
| EA201400767A1 (ru) | Подкожное терапевтическое применение ингибитора dpp-4 | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| GT201300080A (es) | Proceso de elaboracion para derivados de pirimidina | |
| BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| BR112014016805A8 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| IN2015DN00450A (es) | ||
| CR20110608A (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| AU2018347307A1 (en) | Heterocyclic compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |